Cencora, Inc. $COR Shares Sold by CenterBook Partners LP

CenterBook Partners LP reduced its stake in Cencora, Inc. (NYSE:COR) by 83.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,925 shares of the company’s stock after selling 25,193 shares during the quarter. CenterBook Partners LP’s holdings in Cencora were worth $1,539,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Essex Financial Services Inc. lifted its holdings in Cencora by 44.1% in the 3rd quarter. Essex Financial Services Inc. now owns 1,141 shares of the company’s stock valued at $357,000 after purchasing an additional 349 shares in the last quarter. Syon Capital LLC raised its position in shares of Cencora by 13.3% in the third quarter. Syon Capital LLC now owns 3,925 shares of the company’s stock valued at $1,227,000 after buying an additional 462 shares during the last quarter. Advisors Capital Management LLC lifted its stake in shares of Cencora by 2.7% during the third quarter. Advisors Capital Management LLC now owns 2,883 shares of the company’s stock valued at $901,000 after buying an additional 75 shares during the period. NEOS Investment Management LLC boosted its position in Cencora by 97.5% during the third quarter. NEOS Investment Management LLC now owns 18,007 shares of the company’s stock worth $5,628,000 after acquiring an additional 8,890 shares during the last quarter. Finally, Zions Bancorporation National Association UT grew its stake in Cencora by 50.8% in the 3rd quarter. Zions Bancorporation National Association UT now owns 840 shares of the company’s stock worth $263,000 after acquiring an additional 283 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on COR shares. Robert W. Baird set a $415.00 price target on Cencora in a research note on Tuesday, January 13th. Barclays increased their target price on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. TD Cowen raised their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. UBS Group upped their price objective on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Evercore decreased their target price on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $399.00.

Insiders Place Their Bets

In related news, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This represents a 8.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 15,220 shares of company stock worth $5,282,867 over the last quarter. 0.38% of the stock is owned by corporate insiders.

Cencora Trading Down 0.3%

NYSE COR opened at $359.19 on Friday. The firm has a market capitalization of $69.87 billion, a price-to-earnings ratio of 43.17, a PEG ratio of 1.66 and a beta of 0.68. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. Cencora, Inc. has a one year low of $240.72 and a one year high of $377.54. The company’s 50 day moving average price is $349.11 and its 200 day moving average price is $330.32.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. During the same period in the previous year, the firm earned $3.73 earnings per share. Cencora’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.